000099750 001__ 99750
000099750 005__ 20230519145359.0
000099750 0247_ $$2doi$$a10.3389/fphar.2020.592654
000099750 0248_ $$2sideral$$a123270
000099750 037__ $$aART-2021-123270
000099750 041__ $$aeng
000099750 100__ $$aSalehi, B.
000099750 245__ $$aPharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence
000099750 260__ $$c2021
000099750 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099750 5203_ $$aChalcones are among the leading bioactive flavonoids with a therapeutic potential implicated to an array of bioactivities investigated by a series of preclinical and clinical studies. In this article, different scientific databases were searched to retrieve studies depicting the biological activities of chalcones and their derivatives. This review comprehensively describes preclinical studies on chalcones and their derivatives describing their immense significance as antidiabetic, anticancer, anti-inflammatory, antimicrobial, antioxidant, antiparasitic, psychoactive, and neuroprotective agents. Besides, clinical trials revealed their use in the treatment of chronic venous insufficiency, skin conditions, and cancer. Bioavailability studies on chalcones and derivatives indicate possible hindrance and improvement in relation to its nutraceutical and pharmaceutical applications. Multifaceted and complex underlying mechanisms of chalcone actions demonstrated their ability to modulate a number of cancer cell lines, to inhibit a number of pathological microorganisms and parasites, and to control a number of signaling molecules and cascades related to disease modification. Clinical studies on chalcones revealed general absence of adverse effects besides reducing the clinical signs and symptoms with decent bioavailability. Further studies are needed to elucidate their structure activity, toxicity concerns, cellular basis of mode of action, and interactions with other molecules.
000099750 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000099750 590__ $$a5.988$$b2021
000099750 592__ $$a1.143$$b2021
000099750 594__ $$a6.6$$b2021
000099750 591__ $$aPHARMACOLOGY & PHARMACY$$b50 / 279 = 0.179$$c2021$$dQ1$$eT1
000099750 593__ $$aPharmacology (medical)$$c2021$$dQ1
000099750 593__ $$aPharmacology$$c2021$$dQ1
000099750 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000099750 700__ $$aQuispe, C.
000099750 700__ $$aChamkhi, I.
000099750 700__ $$aEl Omari, N.
000099750 700__ $$aBalahbib, A.
000099750 700__ $$aSharifi-Rad, J.
000099750 700__ $$aBouyahya, A.
000099750 700__ $$aAkram, M.
000099750 700__ $$aIqbal, M.
000099750 700__ $$aDocea, A.O.
000099750 700__ $$aCaruntu, C.
000099750 700__ $$aLeyva-Gómez, G.
000099750 700__ $$aDey, A.
000099750 700__ $$aMartorell, M.
000099750 700__ $$aCalina, D.
000099750 700__ $$0(orcid)0000-0001-6969-1055$$aLópez, V.
000099750 700__ $$0(orcid)0000-0002-7972-7119$$aLes, F.
000099750 773__ $$g11 (2021), 592654 [21 pp]$$pFront. pharmacol.$$tFrontiers in Pharmacology$$x1663-9812
000099750 8564_ $$s768660$$uhttps://zaguan.unizar.es/record/99750/files/texto_completo.pdf$$yVersión publicada
000099750 8564_ $$s2765306$$uhttps://zaguan.unizar.es/record/99750/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099750 909CO $$ooai:zaguan.unizar.es:99750$$particulos$$pdriver
000099750 951__ $$a2023-05-18-13:36:53
000099750 980__ $$aARTICLE